Foscarnet sodium composition

A technology of sodium foscarnet and a composition is applied in the field of Th1/Th2 balance disorder caused by hepatitis B virus, which can solve the problems of lack of effective drugs for Th1/Th2 balance, T cell apoptosis, destruction, etc., and achieve a significant therapeutic effect.

Active Publication Date: 2007-04-11
CHIA TAI TIANQING PHARMA GRP CO LTD
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Hypofunction of Th1 induces the body's immune system to fail to produce sufficient TC cells and Th1-type cytokines to kill and destroy virus-infected target cells and inhibit the replication and expression of viral genes, and the body cannot clear the virus in time; Th2-type cytokines further inhibit The function of Th1; the continuous stimulation of viral antigens induces the apoptosis or incompetence of specific T cells, thus forming the host's immune tolerance to viral antigens, and finally leading to the chronic delay of various viral infections
[0005] At present, there is a lack of effective drugs specifically for the treatment of Th1 / Th2 balance disorders in clinical practice

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Example 1 Effect of foscarnet sodium composition on Th1 / Th2 balance in immunocompromised rats.

[0021] Model preparation: Male Wistar rats were subcutaneously injected with cortisone acetate 100 mg / kg once every other day for 14 consecutive days to establish a rat model of immunocompromised function.

[0022] Reagents and experimental methods: IFN-detection kit; IL-4 detection kit. Method: 50 rats, 200g±20g, ♀ half and half. They were randomly divided into 5 groups: normal group, model group and large, medium and small dose administration groups. The model group and each administration group were modeled with the above method. Simultaneously with modeling, intraperitoneal injection of the same volume of foscarnet sodium injection was given, the doses were 200 mg / kg, 400 mg / kg, and 800 mg / kg, respectively, and the model group and normal group were given the same volume of normal saline. After the experiment, the rats in each group were weighed, blood was collected ...

Embodiment 2

[0030] 25 cases of chronic hepatitis B mild to moderate patients, 15 males and 10 females; all cases were diagnosed according to the National Viral Hepatitis Academic Conference in September 2000 by the Infectious and Parasitic Diseases Branch and the Hepatology Branch of the Chinese Medical Association (Xi'an) jointly revised the "Viral Hepatitis Prevention and Control Program". The appeal patients were randomly divided into control group and treatment group. The treatment group was given foscarnet sodium injection 3g / time, twice a day for 4 consecutive weeks.

[0031] Reagents and methods

[0032] Reagents: IFN-detection kit; IL-4 detection kit. Methods: IFN-γ and IL-4 were detected by double-antibody sandwich enzyme-linked assay. Take out the required strips from the airtight bag that has been equilibrated to room temperature, add the specimens and standards of different concentrations (100 μL / well) into the corresponding wells, and then add the biotinylated antibody work...

Embodiment 3

[0038]This experiment investigates the changes of IFN-γ and IL-4 in patients with chronic severe hepatitis B before and after treatment, so as to calculate the effect of drug treatment on Th1 and Th2 functions of patients. Twelve patients with chronic severe hepatitis B (11 males and 1 female) and 9 patients with severe chronic hepatitis B (all males) who did not die during the entire treatment period were selected. Cases were diagnosed according to the "Viral Hepatitis Prevention and Control Program" jointly revised by the Infectious Diseases and Parasitic Diseases Branch and the Hepatology Branch of the Chinese Medical Association in September 2000 at the National Viral Hepatitis Academic Conference (Xi'an). On the basis of comprehensive treatment, both groups were given foscarnet sodium injection 3g / time, twice a day, for 4 consecutive weeks. The changes in the ratio of Th1 / Th2 in patients before and after treatment were detected.

[0039] Reagents and methods

[0040] Re...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a new clinical uses for treatment of Th1/Th2 balance disorder by medicine composition wherein foscarnet sodium as active component, particularly use for Th1/Th2 balance disorder caused by in treatment of hepatitis b virus.

Description

technical field [0001] The invention relates to the field of medicine, in particular, the invention relates to the use of a pharmaceutical composition containing foscarnet sodium as an active ingredient in treating Th1 / Th2 balance disorders, especially the Th1 / Th2 balance disorders caused by hepatitis B virus. Background technique [0002] Current clinical studies have shown that Th1 / Th2 balance disorders are the main mechanism leading to the chronic persistence of various diseases, especially in the conversion of acute inflammation of specific organs caused by various viruses to chronic inflammation, which plays an important role. Therefore, Th1 / Th2 balance disorder is a hotspot in the research of chronic viral inflammation. [0003] Helper T cells are one of the main cells that secrete and produce cytokines. They are divided into two subgroups, Th1 and Th2. The Th1 subgroup secretes IFN-γ, IL-2, LT-α, etc., and mainly promotes the body’s cell-mediated immune response , wh...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/662A61P1/16A61P31/12
Inventor 沈军徐中南
Owner CHIA TAI TIANQING PHARMA GRP CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap